Table 3.
Secondary hormonal treatment approaches (n = 174).
| Value | |
|---|---|
| Antiandrogen withdrawal; n (%) | 99 (56.9) |
|
| |
| LHRH agonists; n (%) | 59 (33.9) |
| Continue the patient on initial LHRH agonist | 51 (86.4) |
| Switch to a different LHRH agonist | 8 (13.6) |
|
| |
| Addition of antiandrogens; n (%) | 47 (27.0) |
| Nonsteroidal antiandrogens | 41 (87.2) |
| Steroidal antiandrogens | 6 (12.8) |
|
| |
| Adrenal testosterone inhibitors; n (%)† | 26 (14.9) |
| Ketoconazole | 21 (84.0) |
| Corticoids | 4 (16.0) |
|
| |
| Continue the patient on initial treatment; n (%) | 25 (14.4) |
|
| |
| Antiandrogen replacement; n (%) | 12 (6.9) |
| Nonsteroids | 8 (66.7) |
| Steroids | 4 (33.3) |
|
| |
| Estrogenic compounds | 8 (4.6) |
Data are expressed as n (percentage of total second hormonal manipulation and option used). Percentages may add up more than 100% as patients could receive more than one hormonal manipulation. LHRH: luteinising hormone-releasing hormone. †One missing data.